The efficacy of fructose-1,6-bisphosphate in suppressing status epilepticus in developing rats

Research output: Contribution to journalArticlepeer-review


Purpose: Treatment of pediatric status epilepticus (SE) remains challenging as up to 50 % of patients are refractory to conventional anti-seizure medications. The glycolytic intermediate, fructose-1,6-bisphosphate (FBP), has been reported to exert significant anticonvulsant effects in both adult animals and in in vitro models of seizures. This study aims to examine FBP efficacy in controlling seizures in a rat model of juvenile SE. Methods: Sprague Dawley rats (P11-P17) were injected with pilocarpine (300 mg/kg, i.p.) to induce SE, which was monitored by video-electroencephalography (v-EEG). Thirty minutes into SE, FBP was administrated (500 or 1000 mg/kg, i.p.). v-EEG recording was continued for ∼60 additional minutes to assess the anticonvulsant effect of FBP, compared with vehicle (saline) treatment. Results: SE consistently occurred in rat pups 10−15 min after pilocarpine injection and persisted over the 90-min recording period. Neither saline nor a lower dose of FBP (500 mg/kg) treatment stopped behavioral and electrographic seizures. At higher doses (1000 mg/kg), FBP terminated SE in ∼15 min in 60 % (6 of 10) of the rat pups. Conclusion: The endogenous glycolytic metabolite, FBP, promptly suppresses ongoing seizure activity and represents a potential alternative metabolic therapy to improve the treatment of SE in the juvenile age range.

Original languageEnglish (US)
Article number106500
JournalEpilepsy Research
StatePublished - Dec 2020


  • Anti-seizure medication (ASM)
  • Developing brain
  • Glycolysis
  • Metabolism
  • Pediatric seizures

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology


Dive into the research topics of 'The efficacy of fructose-1,6-bisphosphate in suppressing status epilepticus in developing rats'. Together they form a unique fingerprint.

Cite this